On January 17, 2024 Certis Oncology Solutions (Certis), a precision oncology and translational science company focused on combining AI-directed drug development with advanced functional testing, reported that it raised $10 million in a Series C funding round, bringing total raised to $42 million (Press release, Certis Oncology Solutions, JAN 17, 2024, View Source [SID1234639299]). The company also named John R. Tozzi Chairman of its Board of Directors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We welcome John’s leadership and this additional investment at this critical inflection point for our company," said Peter Elman, President and CEO of Certis. "Now serving more than 120 oncology therapeutics companies, we have established the necessary business traction to see a clear path to profitable growth. At the same time, ongoing validation studies give us great confidence that our proprietary CertisAI predictive oncology platform soon will be able to deliver truly personalized cancer treatment at scale."
New Certis Board of Directors Chairman, John Tozzi, who also serves as the Certis Chairman of the Executive and Finance Committees, led the company’s last two internal funding rounds, as well as this most recent raise in which 94% of the company’s top 50 investors participated. "Our investors are passionate about the company’s patient-focused mission and 100% behind its three-pronged strategy for creating shareholder value: building a best-in-class bank of advanced tumor models for cancer research, developing disruptive AI-based intellectual property, and generating services revenue from very specialized contract research to help fund R&D," he said. In 1982 Mr. Tozzi founded Cambridge Investments LLC, an investment management firm, and continues to serve as its CEO and CIO.